Oncolytic adenovirus KD02 vector carrying dual immune activation ligands as well as preparation method and application of oncolytic adenovirus KD02 vector
By deleting the Gp19k and ADP fragments of the E3 region in the oncolytic adenovirus vector and inserting the mCD40L and OX40L coding regions, the problems of uncertain expression and unclear location of existing vectors were solved, and efficient immune activation and anti-tumor effects were achieved.
CN119932112APending Publication Date: 2025-05-06WUHAN KAIDEJINUO BIOTECHNOLOGY CO LTD
Patent Information
- Application Number
- CN202510068187.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-01-16
- Publication Date
- 2025-05-06
AI Technical Summary
Technical Problem
When existing oncolytic adenovirus vectors carry immune targets, their expression uncertainty and unclear location affect their anti-tumor immune effect.
Method used
By designing the recombinant plasmid, the Gp19k and ADP fragments of the adenovirus E3 region were deleted, and the coding regions of mCD40L and OX40L were inserted at their positions to form an oncolytic adenovirus KD02 vector carrying dual immune activation ligands.
Benefits of technology
Effective expression of mCD40L and OX40L is achieved, which enhances the anti-tumor immune response, increases the progeny virus load of tumor cells, and significantly inhibits tumor growth.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN119932112A_ABST
Abstract
The invention relates to the technical field of biological medicines, in particular to an oncolytic adenovirus KD02 carrier carrying dual immune activation ligands as well as a preparation method and application of the oncolytic adenovirus KD02 carrier. A plasmid skeleton of the recombinant plasmid is type-5 adenovirus, the recombinant plasmid has an E3 region nucleotide sequence with double deletion of a Gp19k fragment and an ADP fragment, and the E3 region nucleotide sequence comprises a nucleotide sequence of an mCD40L coding region and a nucleotide sequence of an OX40L coding region. The virus obtained by the recombinant plasmid can be used for well expressing mCD40L and OX40L; according to the oncolytic adenovirus KD02 carrier carrying the dual immune activation ligands, target genes mCD40L and OX40L are carried in the genes, the tumor immune microenvironment can be remodeled, the tumor transfection efficiency is high, the efficient immune activation characteristic is achieved, and the oncolytic adenovirus KD02 carrier has wide application prospects in preparation of various preparations for treating tumors.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Preparation and application of prostate cancer targeting adenovirus
CN101928696A
Oncolytic adenovirus recombinant vector, construction method and application thereof
CN117568405A
Novel oncolytic adenovirus vector as well as construction method and application thereof
CN118853767A
Adenovirus constructs and methods
US20170314044A1